-
18 hours ago | 
ophthalmologytimes.com | Sheryl Stevenson
Alcon’s announcement of the FDA approval for its acoltremon ophthalmic solution 0.003% (Tryptry; formerly AR-15512) for the treatment of signs and symptoms of dry eye disease (DED)1,2 brings to market a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production.
-
3 days ago | 
ophthalmologytimes.com | Sheryl Stevenson |Hattie Hayes
Author(s):,At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial. At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles, California, the Eye Care Network spoke with dozens of presenters about the data they brought to the meeting. Steven R. Sarkisian Jr., MD, ABO, presented data from an FDA clinical trial of a travopost intracameral implant.
-
1 week ago | 
ophthalmologytimes.com | Eric D. Donnenfeld |Sheryl Stevenson |Hattie Hayes
Eric D. Donnenfeld, MD, presented clinical trial results evaluating the impact of lifitegrast on dry eye disease (DED) symptomatology and biomarkers—findings shared at the 2025 American Society of Cataract and Refractive Surgery Annual Meeting, held April 25–28 in Los Angeles, California. Lifitegrast, an immunomodulator that targets T cell pathways, stands out for its ability to modulate multiple aspects of the inflammatory cascade underlying DED.
-
1 week ago | 
ophthalmologytimes.com | Amar Shah |Sheryl Stevenson |Hattie Hayes
Author(s):,A significant proportion of cataract surgery patients exhibit hyperosmolar tear film both before and 1 month after surgery, underscoring the importance of preoperative screening and postoperative management to optimize visual outcomes. Amar P.
-
1 week ago | 
ophthalmologytimes.com | Brandon D. Ayres |Sheryl Stevenson
Brandon D. Ayres, MD, highlighted the clinical benefits of using a 27-gauge, 22,000-cpm vitrectomy probe for pars plana anterior vitrectomy in his presentation at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25–28 in Los Angeles, California.
-
3 weeks ago | 
optometrytimes.com | Karl G. Stonecipher |Emily Kaiser Maharjan |Hattie Hayes |Sheryl Stevenson
May 15, 2025By At this year’s ASCRS meeting, the Eye Care Network sat down with Karl Stonecipher, MD, to discuss some of the most exciting clinical outcomes and technological advancements in refractive surgery—particularly in the treatment of high myopia. Stonecipher shared insights from a recent trial using the Teneo laser platform (Bausch + Lomb), highlighting its speed, precision, and patient-centered design.
-
3 weeks ago | 
ophthalmologytimes.com | Jason Bacharach |Sheryl Stevenson |Hattie Hayes
Perfluorohexylactane may offer a fast-acting option for dry eye symptom relief, showing measurable benefits within minutes of application, explained Jason Bacharach, MD, who presented findings on the agent’s early efficacy at the 2025 American Society of Cataract and Refractive meeting, held April 25 to 28 in Los Angeles, California.
-
3 weeks ago | 
optometrytimes.com | AnnMarie Hipsley |Emily Kaiser Maharjan |Sheryl Stevenson |Hattie Hayes
At the 2025 ASCRS meeting in Los Angeles, a concept was shared by AnnMarie Hipsley, DPT, PhD, for optometrists seeking to stay at the forefront of precision ocular care—the Digital Twin. More than a buzzword, a digital twin represents a virtual simulation of a real-world anatomical system, in this case, the human eye.
-
4 weeks ago | 
ophthalmologytimes.com | Deborah Ristvedt |Sheryl Stevenson |Hattie Hayes
Author(s):,Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians. Deb Ristvedt, DO, moderated a session titled Medications, Lasers, and Lifestyle, highlighting the rapid evolution of glaucoma treatment paradigms at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California.
-
1 month ago | 
ophthalmologytimes.com | Michael Rivers |Hattie Hayes |Sheryl Stevenson
CommentaryVideoMay 6, 2025Author(s):,The first SightLine meeting, held pre-ASCRS, reveals insights on physician-industry relationships, mentorship opportunities, and the practical applications of AI in healthcare.
